[go: up one dir, main page]

TN2009000270A1 - Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase - Google Patents

Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase

Info

Publication number
TN2009000270A1
TN2009000270A1 TNP2009000270A TN2009000270A TN2009000270A1 TN 2009000270 A1 TN2009000270 A1 TN 2009000270A1 TN P2009000270 A TNP2009000270 A TN P2009000270A TN 2009000270 A TN2009000270 A TN 2009000270A TN 2009000270 A1 TN2009000270 A1 TN 2009000270A1
Authority
TN
Tunisia
Prior art keywords
rho
kinase
inhibitors
substituted isoquinoline
isoquinolinone derivatives
Prior art date
Application number
TNP2009000270A
Other languages
English (en)
Inventor
Oliver Plettenburg
Armin Hofmeister
Joachim Brendel
Matthias Lohn
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38191090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000270(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of TN2009000270A1 publication Critical patent/TN2009000270A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
TNP2009000270A 2006-12-27 2009-06-25 Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase TN2009000270A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06026898 2006-12-27
PCT/EP2007/011163 WO2008077550A1 (fr) 2006-12-27 2007-12-19 Dérivés d'isoquinoline et d'isoquinolinone substitués inhibiteurs de la rho-kinase

Publications (1)

Publication Number Publication Date
TN2009000270A1 true TN2009000270A1 (en) 2010-10-18

Family

ID=38191090

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000270A TN2009000270A1 (en) 2006-12-27 2009-06-25 Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase

Country Status (27)

Country Link
US (2) US8278294B2 (fr)
EP (1) EP2102187B1 (fr)
JP (1) JP5421783B2 (fr)
KR (1) KR101517154B1 (fr)
CN (1) CN101616909B (fr)
AR (1) AR064533A1 (fr)
AU (1) AU2007338406B2 (fr)
BR (1) BRPI0720862A2 (fr)
CA (1) CA2673916C (fr)
CL (1) CL2007003822A1 (fr)
CO (1) CO6321138A2 (fr)
CR (1) CR10812A (fr)
DO (1) DOP2009000163A (fr)
EC (1) ECSP099466A (fr)
IL (1) IL199541A (fr)
MA (1) MA31021B1 (fr)
MX (1) MX2009005825A (fr)
MY (1) MY150746A (fr)
NI (1) NI200900107A (fr)
NO (1) NO20092421L (fr)
NZ (1) NZ577981A (fr)
RU (1) RU2455302C2 (fr)
TN (1) TN2009000270A1 (fr)
TW (1) TWI435723B (fr)
UY (1) UY30840A1 (fr)
WO (1) WO2008077550A1 (fr)
ZA (1) ZA200903550B (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1910297B1 (fr) 2005-07-11 2016-05-25 Aerie Pharmaceuticals, Inc. Composes isoquinoliniques
JP5235887B2 (ja) 2006-09-20 2013-07-10 アエリー ファーマシューティカルズ インコーポレイテッド Ｒｈｏキナーゼ阻害剤
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8455514B2 (en) 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
CN102099036B (zh) 2008-06-03 2015-05-27 英特芒尼公司 用于治疗炎性疾患和纤维化疾患的化合物和方法
MX2010013867A (es) * 2008-06-24 2011-02-24 Sanofi Aventis Derivados de isoquinolina e isoquinolinona bi- y policiclicos sustituidos.
KR101638326B1 (ko) * 2008-06-24 2016-07-12 사노피 Ｒｈｏ 키나제 억제제로서의 치환된 이소퀴놀린 및 이소퀴놀리논
MX2010013974A (es) * 2008-06-24 2011-01-14 Sanofi Aventis Isoquinolinas e isoquinolinonas 6-sustituidas.
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US8394826B2 (en) 2009-05-01 2013-03-12 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
DK2729461T3 (en) * 2011-07-08 2016-04-11 Sanofi Sa Polymorphs of 6- (piperidin-4-yloxy) -2H-isoquinolin-1-one hydrochloride
WO2013007518A1 (fr) * 2011-07-08 2013-01-17 Sanofi Solvates cristallins de chlorhydrate de 6-(pipéridin-4-yloxy)-2h-isoquinolin-1-one
JP6030644B2 (ja) 2011-07-08 2016-11-24 サノフイ 置換されたフェニル化合物
CN103160571A (zh) * 2011-12-09 2013-06-19 彩虹天健康科技研究(北京)有限责任公司 磷酸化肌球蛋白和驱动蛋白的激酶的发现
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
EP2740458B1 (fr) 2012-12-06 2016-08-03 IP Gesellschaft für Management mbH Emballage comprenant des formes de sel de sodium de 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phényl]-benzenesulfonamide
EP4335507A3 (fr) 2013-03-15 2024-06-05 Aerie Pharmaceuticals, Inc. Polythérapie
DK3290407T3 (da) 2013-10-18 2020-03-23 Celgene Quanticel Res Inc Bromodomæneinhibitorer
FR3017868A1 (fr) 2014-02-21 2015-08-28 Servier Lab Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP6525437B2 (ja) * 2014-04-02 2019-06-05 インターミューン， インコーポレイテッド 抗線維性ピリジノン
MX2017008520A (es) 2014-12-24 2018-03-01 Gilead Sciences Inc Compuestos de pirimidina fusionada para el tratamiento del virus de inmunodeficiencia humana (vih).
TWI699355B (zh) 2014-12-24 2020-07-21 美商基利科學股份有限公司 喹唑啉化合物
BR112017013440A2 (pt) 2014-12-24 2018-01-09 Gilead Sciences, Inc. compostos de isoquinolina para o tratamento de hiv
AR104259A1 (es) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
JP6832946B2 (ja) 2015-11-17 2021-02-24 アエリエ ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤およびその中間体の調製方法
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
JP2019513804A (ja) 2016-04-18 2019-05-30 セルジーン クオンティセル リサーチ，インク． 治療用化合物
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
BR112019003945A2 (pt) 2016-08-31 2019-05-21 Aerie Pharmaceuticals, Inc. composições oftálmicas
US10865201B2 (en) * 2016-09-12 2020-12-15 Valo Health, Inc. Bicyclic compounds useful as GPR120 modulators
WO2018049324A1 (fr) 2016-09-12 2018-03-15 Numerate, Inc. Composés monocycliques utiles comme modulateurs de gpr120
MX2019011784A (es) 2017-03-31 2019-11-18 Aerie Pharmaceuticals Inc Compuestos de aril ciclopropil-amino-isoquinolinil amida.
CA3090270A1 (fr) * 2018-02-02 2019-08-08 Genentech, Inc. Compose pharmaceutique, sels de celui-ci, formulations de celui-ci, et procedes de fabrication et d'utilisation de celui-ci
CA3112391A1 (fr) 2018-09-14 2020-03-19 Aerie Pharmaceuticals, Inc. Composes d'amide aryl cyclopropyl-amino-isoquinolinyl
CN109180586B (zh) * 2018-10-10 2022-03-08 成都理工大学 作为Rho激酶抑制剂的六氢氮杂卓-4-基氧基苯甲酰胺类化合物
TWI721624B (zh) 2018-10-31 2021-03-11 美商基利科學股份有限公司 經取代之6-氮雜苯并咪唑化合物
PE20211655A1 (es) 2018-10-31 2021-08-24 Gilead Sciences Inc Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1
EP3972695A1 (fr) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Exo-méthylène-oxindoles substitués qui sont des inhibiteurs de hpk1/map4k1
CA3188722A1 (fr) * 2020-08-27 2022-03-03 Thomas Macallister Methodes de traitement de declin cognitif lie a l'age
US11738030B2 (en) 2021-10-30 2023-08-29 Aneuryst, Inc. Treatments for disturbed cerebral homeostasis
WO2023085369A1 (fr) 2021-11-11 2023-05-19 学校法人同志社 Préparation de cryoconservation pour cellules endothéliales cornéennes et procédé de production de ladite préparation de cryoconservation
IL318082A (en) * 2022-08-01 2025-02-01 Valo Health Inc Process for preparing 1-(2H)-ISOQUINOLINONE-type materials modified at position 6, and intermediates obtained in the process

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2485537B2 (fr) 1977-04-13 1986-05-16 Anvar Dipyrido(4,3-b)(3,4-f)indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant
JPH06501921A (ja) 1990-07-31 1994-03-03 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 選択されたハロカーボンの触媒平衡化
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9516709D0 (en) 1995-08-15 1995-10-18 Zeneca Ltd Medicament
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
EP0956865B2 (fr) 1996-08-12 2010-08-18 Mitsubishi Tanabe Pharma Corporation MEDICAMENTS COMPRENANT UN INHIBITEUR DE LA Rho KINASE
JPH1087629A (ja) 1996-09-18 1998-04-07 Fujisawa Pharmaceut Co Ltd 新規イソキノリン誘導体、およびその医薬用途
AU8872198A (en) 1997-08-29 1999-03-22 Zeneca Limited Aminometyl oxooxazolidinyl benzene derivatives
TW575567B (en) * 1998-10-23 2004-02-11 Akzo Nobel Nv Serine protease inhibitor
GB9912701D0 (en) 1999-06-01 1999-08-04 Smithkline Beecham Plc Novel compounds
US6541456B1 (en) 1999-12-01 2003-04-01 Isis Pharmaceuticals, Inc. Antimicrobial 2-deoxystreptamine compounds
BR0107732A (pt) 2000-01-20 2003-03-11 Eisai Ltd Método para prevenir ou tratar uma doença
US7217722B2 (en) * 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
WO2001064238A2 (fr) 2000-02-29 2001-09-07 Curis, Inc. Procédés et compositions permettant de réguler les adipocytes
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
GB0013060D0 (en) 2000-05-31 2000-07-19 Astrazeneca Ab Chemical compounds
AU2001296008A1 (en) 2000-10-27 2002-05-06 Takeda Chemical Industries Ltd. Process for preparing substituted aromatic compounds and intermediates therefor
WO2002055496A1 (fr) 2001-01-15 2002-07-18 Glaxo Group Limited Derives aryle de piperidine et de piperazine comme inducteurs de l'expression du recepteur ldl
SE0101038D0 (sv) 2001-03-23 2001-03-23 Astrazeneca Ab Novel compounds
WO2002088101A2 (fr) 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Inhibiteurs de bace
EP1403255A4 (fr) 2001-06-12 2005-04-06 Sumitomo Pharma Inhibiteurs de rho kinase
GB0117899D0 (en) 2001-07-23 2001-09-12 Astrazeneca Ab Chemical compounds
WO2003024450A1 (fr) 2001-09-20 2003-03-27 Eisai Co., Ltd. Methodes de traitement des maladies a prions
SE0104340D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
EP1541559A4 (fr) * 2002-07-22 2007-08-22 Asahi Kasei Pharma Corp Derive d'isoquinoline 5-substituee
US7615564B2 (en) 2002-09-12 2009-11-10 Kirin Beer Kabushiki Kaisha Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same
BRPI0407976A (pt) * 2003-03-03 2006-03-07 Hoffmann La Roche tetrahidroisoquinolinas substituìdas em 2,5 e 2,6 para uso como moduladores de 5-ht6
WO2004105757A2 (fr) 2003-05-29 2004-12-09 Schering Aktiengesellschaft Utilisation des inhibiteurs de la rho kinase dans le traitement de l'anevrisme et de l'hypertrophie cardiaque
WO2004113297A2 (fr) 2003-06-24 2004-12-29 Neurosearch A/S Derives de noyaux aza et utilisation de ceux-ci comme inhibiteurs de la recapture des neurotransmetteurs monoaminergiques
AU2004275720B2 (en) 2003-09-23 2008-04-24 Merck Sharp & Dohme Corp. Isoquinoline potassium channel inhibitors
EP1667982B1 (fr) 2003-09-23 2013-07-31 Merck Sharp & Dohme Corp. Inhibiteurs du canal potassique d'isoquinolinone
US20050067037A1 (en) 2003-09-30 2005-03-31 Conocophillips Company Collapse resistant composite riser
EP1671962A1 (fr) 2003-10-10 2006-06-21 Ono Pharmaceutical Co., Ltd. Nouveau compose heterocyclique fondu et utilisation correspondante
WO2005054202A1 (fr) 2003-11-25 2005-06-16 Eli Lilly And Company Derives de 7-phenyl-isoquinoline-5-sulfonylamino en tant qu'inhibiteurs de akt (proteine kinase b)
JP2005232175A (ja) * 2004-01-21 2005-09-02 Asahi Kasei Pharma Kk ５−置換イソキノリン医薬
WO2005074535A2 (fr) 2004-01-30 2005-08-18 Eisai Co., Ltd. Inhibiteurs de cholinesterase pour des troubles de la colonne vertebrale
EP1729761A4 (fr) 2004-03-05 2008-09-03 Eisai Co Ltd Traitement de cadasil avec des inhibiteurs de la cholinesterase
SE0400850D0 (sv) 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
PT1899322E (pt) * 2005-06-28 2009-11-09 Sanofi Aventis Derivados de isoquinolina como inibidores de rho-cinase
NI200800024A (es) 2005-07-26 2009-03-03 Derivados de ciclohexilaminisoquinolona en calidad inhibidores de rho-quinasa
EP2385047B1 (fr) * 2005-07-26 2013-05-29 Sanofi Dérivés de l'isoquinoléine à substitution pipéridinyle
TW200745101A (en) 2005-09-30 2007-12-16 Organon Nv 9-Azabicyclo[3.3.1]nonane derivatives
TW200738682A (en) * 2005-12-08 2007-10-16 Organon Nv Isoquinoline derivatives
US7618985B2 (en) * 2005-12-08 2009-11-17 N.V. Organon Isoquinoline derivatives
US7893088B2 (en) 2006-08-18 2011-02-22 N.V. Organon 6-substituted isoquinoline derivatives
CA2673921C (fr) 2006-12-27 2015-10-20 Sanofi-Aventis Nouvelle isoquinoline substituee et derives d'isoquinolinone
RU2468011C2 (ru) 2006-12-27 2012-11-27 Санофи-Авентис Замещенные циклоалкиламином производные изохинолина и изохинолинона

Also Published As

Publication number Publication date
CL2007003822A1 (es) 2009-10-16
RU2455302C2 (ru) 2012-07-10
MX2009005825A (es) 2009-06-16
US8461144B2 (en) 2013-06-11
CR10812A (es) 2009-08-12
EP2102187B1 (fr) 2015-04-01
IL199541A (en) 2014-08-31
HK1140201A1 (en) 2010-10-08
US8278294B2 (en) 2012-10-02
AR064533A1 (es) 2009-04-08
UY30840A1 (es) 2008-07-31
NI200900107A (es) 2010-01-15
BRPI0720862A2 (pt) 2014-02-25
EP2102187A1 (fr) 2009-09-23
NO20092421L (no) 2009-09-17
ECSP099466A (es) 2009-07-31
CN101616909B (zh) 2013-09-11
TWI435723B (zh) 2014-05-01
US20120316152A1 (en) 2012-12-13
AU2007338406A1 (en) 2008-07-03
JP2010514715A (ja) 2010-05-06
CO6321138A2 (es) 2011-09-20
KR20090094337A (ko) 2009-09-04
KR101517154B1 (ko) 2015-04-30
WO2008077550A1 (fr) 2008-07-03
AU2007338406B2 (en) 2012-08-09
MA31021B1 (fr) 2009-12-01
DOP2009000163A (es) 2009-08-31
CA2673916A1 (fr) 2008-07-03
CN101616909A (zh) 2009-12-30
NZ577981A (en) 2011-12-22
US20100063025A1 (en) 2010-03-11
RU2009128645A (ru) 2011-02-10
ZA200903550B (en) 2010-04-28
CA2673916C (fr) 2015-02-17
MY150746A (en) 2014-02-28
JP5421783B2 (ja) 2014-02-19
TW200848043A (en) 2008-12-16

Similar Documents

Publication Publication Date Title
TN2009000270A1 (en) Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase
TN2009000273A1 (en) New substituted isoquinoline and isoquinolinone derivatives
MY155279A (en) Substituted isoquinoline and isoquinolinone derivatives
MX2009005967A (es) Derivados de isoquinolina e isoquinolinona sustituidos con cicloalquilamina.
TN2009000269A1 (en) Cycloalkylamine substituted isoquinolone derivatives
MY151953A (en) Cycloalkylamine substituted isoquinoline derivatives
TNSN08039A1 (en) Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors
MY146037A (en) Isoquinoline derivatives as inhibitors of rho-kinase
ATE505458T1 (de) Cycloalkylaminsubstituierte isochinolon- und isochinolinonderivate
TNSN08038A1 (en) Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors
MY157330A (en) Substituted isoquinolinones as rho kinase inhibitors
AU2009262516A8 (en) 6-substituted isoquinolines and isoquinolinones
TN2010000589A1 (en) Substituted dsoquinolines and isoquinodlinones as rho kinase inhibitors
TN2010000588A1 (en) Substituted isoquinolines and isoquinolinones